Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Revolo Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : CordenPharma will Provide manufacturing support for Revolo Bio’s first-in-class peptide and immune system resetting drug product, ‘1104, for its upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease.
Brand Name : ‘1104
Molecule Type : Peptide
Upfront Cash : Undisclosed
April 15, 2021
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Revolo Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : mRNA-1273
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Moderna Extends Lipid Supply For Coronavirus Vaccine
Details : The amended agreement now includes CordenPharma Chenôve (FR) and CordenPharma Colorado (US) for the manufacture of larger-scale volumes of lipids, while continuing to draw upon CordenPharma Switzerland’s long-standing reputation as a leader in special...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 28, 2020
Lead Product(s) : mRNA-1273
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
